GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

ABSTRACT:

Objective

GM1 ganglioside has been suggested as a treatment for Parkinson's disease (PD), potentially having symptomatic and disease modifying effects. The current pilot imaging study was performed to examine effects of GM1 on dopamine transporter binding, as a surrogate measure of disease progression, studied longitudinally.

Methods

Positron emission tomography (PET) imaging data were obtained from a subset of subjects enrolled in a delayed start clinical trial of GM1 in PD [1]: 15 Early-start (ES) subjects, 14 Delayed-start (DS) subjects, and 11 Comparison (standard-of-care) subjects. Treatment subjects were studied over a 2.5 year period while Comparison subjects were studied over 2 years. Dynamic PET scans were performed over 90 min following injection of [(11)C]methylph

SUBMITTER: Schneider JS 

PROVIDER: S-EPMC4545312 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature